partnering

News

Genmab takes aims at immuno-oncology antibody conjugates wit...

Genmab has enlisted the help of Bolt Biotherapeutics to develop a new class of immune-boosting antibody conjugates for cancer in a deal that could be worth up to $880 million.

News

Healios raises £7m to expand digital mental health services

Digital therapy specialist Healios has raised £7 million in new financing that will be used to expand its suite of mental health services, at a time when demand is soaring in the NHS.

News

Lilly buys into MiNA's protein-boosting RNA tech in $1.25bn ...

UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to

News

Vertex eyes controllable genetic drugs with $1.3bn Obsidian ...

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform.

News

Artifical intelegence DNA molecule. DNA is converted into a binary code. Concept binary code genome. Abstract technology science, concept artifical Dna, 3D illustration

Novartis expands in radio-oncology again with $1.3bn Artios ...

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus alliance with UK biotech Artios Pharma to develop precision medicines f

News

Lilly cuts a $960m deal with Rigel on RIP kinase

Eli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new class of drugs with potential in autoimmune and inflammatory disease, paying $125 million u

Genmab takes aims at immuno-oncology antibody conjugates wit...

Healios raises £7m to expand digital mental health services

Lilly buys into MiNA's protein-boosting RNA tech in $1.25bn ...

Vertex eyes controllable genetic drugs with $1.3bn Obsidian ...

Novartis expands in radio-oncology again with $1.3bn Artios ...

Lilly cuts a $960m deal with Rigel on RIP kinase

ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...

Discover a new era of healthcare panel engagement: Grounded ...

partnering

Editor's Picks